Advertisement
Journal of Clinical Oncology  
Search for:
Limit by:
  Browse by Subject or Issue
Home Search or Browse JCO My JCO Subscriptions Customer Service Site Map

Journal of Clinical Oncology, Vol 24, No 24 (August 20), 2006: pp. 3946-3952
© 2006 American Society of Clinical Oncology.
DOI: 10.1200/JCO.2005.05.1490
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a colleague
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Save to my personal folders
Right arrow Download to citation manager
Right arrowRights & Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Heinemann, V.
Right arrow Articles by Wilkowski, R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Heinemann, V.
Right arrow Articles by Wilkowski, R.
Related Articles
Right arrowRelated Correspondence

Randomized Phase III Trial of Gemcitabine Plus Cisplatin Compared With Gemcitabine Alone in Advanced Pancreatic Cancer

Volker Heinemann, Detlef Quietzsch, Frank Gieseler, Michael Gonnermann, Herbert Schönekäs, Andreas Rost, Horst Neuhaus, Caroline Haag, Michael Clemens, Bernard Heinrich, Ursula Vehling-Kaiser, Martin Fuchs, Doris Fleckenstein, Wolfgang Gesierich, Dirk Uthgenannt, Hermann Einsele, Axel Holstege, Axel Hinke, Andreas Schalhorn, Ralf Wilkowski

From the Medizinische Klinik und Poliklinik III, Klinikum Grosshadern; Krankenhaus Bogenhausen; Klinikum Neuperlach München; Krankenhaus München-Harlaching; Klinik für Strahlentherapie, Klinikum Grosshadern, Munich; Klinikum Chemnitz; Universitätsklinik Kiel, Kiel; Evangelisches Krankenhaus Dinslaken, Dinslaken; Klinikum Nürnberg Nord, Nürnberg; Klinikum Darmstadt, Darmstadt; Evangelisches Krankenhaus Düsseldorf, Düsseldorf; Medizinische Fakultät der TU Dresden, Dresden; Mutterhaus der Borromäerinnen Trier, Trier; Onkologische Praxis Augsburg, Augsburg; Onkologische Praxis Landshut; Klinikum Landshut, Landshut; Medizinische Universität zu Lübeck, Lübeck; Medizinische Klinik II, Universität Würzburg, Würzberg; Wissenchaftlicher Service Pharma (WiSP), Langenfeld, Germany

Address reprint requests to Volker Heinemann, MD, PhD, Medical Clinic III, Klinikum Grosshadern, Marchioninistrasse 15, 81377 Munich, Germany; e-mail: Volker.Heinemann{at}med.uni-muenchen.de

PURPOSE: To compare the effectiveness and tolerability of gemcitabine plus cisplatin with single-agent gemcitabine as first-line chemotherapy for locally advanced or metastatic pancreatic cancer.

PATIENTS AND METHODS: Patients with advanced adenocarcinoma of the pancreas were randomly assigned to receive either gemcitabine 1,000 mg/m2 and cisplatin 50 mg/m2 given on days 1 and 15 of a 4-week cycle (GemCis arm) or gemcitabine alone at a dose of 1,000 mg/m2 on days 1, 8, and 15 of a 4-week regimen (Gem arm). The primary end point was overall survival; secondary end points were progression-free survival, response rate, safety, and quality of life.

RESULTS: One hundred ninety-five patients were enrolled and showed baseline characteristics well balanced between treatment arms. Combination treatment in the GemCis arm was associated with a prolonged median progression-free survival (5.3 months v 3.1 months; hazard ratio [HR] = 0.75; P = .053). Also, median overall survival was superior for patients treated in the GemCis arm as compared with the Gem arm (7.5 v 6.0 months), an advantage which did not, however, reach statistical significance (HR = 0.80; P = .15). Tumor response rates were comparable between treatment arms (10.2% v 8.2%). The rate of stable disease was, however, greater in the combination arm (60.2% v 40.2%; P < .001). Grade 3 to 4 hematologic toxicity did not exceed 15% in both treatment arms.

CONCLUSION: These results support the efficacy and safety of an every-2-weeks treatment with gemcitabine plus cisplatin. Median overall survival and progression-free survival were more favorable in the combination arm as compared with gemcitabine alone, although the difference did not attain statistical significance.

Authors' disclosures of potential conflicts of interest and author contributions are found at the end of this article.


Related Correspondence

  • Gemcitabine Plus Cisplatin in Advanced Pancreatic Cancer
    Robert R. McWilliams and Steven R. Alberts
    JCO 2007 25: 1142 [Full Text]


This article has been cited by other articles:


Home page
 JCOHome page
J. Bernhard, D. Dietrich, W. Scheithauer, D. Gerber, G. Bodoky, T. Ruhstaller, B. Glimelius, E. Bajetta, J. Schuller, P. Saletti, et al.
Clinical Benefit and Quality of Life in Patients With Advanced Pancreatic Cancer Receiving Gemcitabine Plus Capecitabine Versus Gemcitabine Alone: A Randomized Multicenter Phase III Clinical Trial--SAKK 44/00-CECOG/PAN.1.3.001
J. Clin. Oncol., August 1, 2008; 26(22): 3695 - 3701.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
M. S. Pino, M. Balsamo, F. Di Modugno, M. Mottolese, M. Alessio, E. Melucci, M. Milella, D. J. McConkey, U. Philippar, F. B. Gertler, et al.
Human Mena+11a Isoform Serves as a Marker of Epithelial Phenotype and Sensitivity to Epidermal Growth Factor Receptor Inhibition in Human Pancreatic Cancer Cell Lines
Clin. Cancer Res., August 1, 2008; 14(15): 4943 - 4950.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
Y. J. Chua and J. R. Zalcberg
Pancreatic cancer--is the wall crumbling?
Ann. Onc., July 1, 2008; 19(7): 1224 - 1230.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
J. Nieto, M. L. Grossbard, and P. Kozuch
Metastatic Pancreatic Cancer 2008: Is the Glass Less Empty?
Oncologist, May 1, 2008; 13(5): 562 - 576.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
S. Boeck and V. Heinemann
Second-Line Therapy in Gemcitabine-Pretreated Patients With Advanced Pancreatic Cancer
J. Clin. Oncol., March 1, 2008; 26(7): 1178 - 1179.
[Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
D. Laheru, E. Lutz, J. Burke, B. Biedrzycki, S. Solt, B. Onners, I. Tartakovsky, J. Nemunaitis, D. Le, E. Sugar, et al.
Allogeneic Granulocyte Macrophage Colony-Stimulating Factor-Secreting Tumor Immunotherapy Alone or in Sequence with Cyclophosphamide for Metastatic Pancreatic Cancer: A Pilot Study of Safety, Feasibility, and Immune Activation
Clin. Cancer Res., March 1, 2008; 14(5): 1455 - 1463.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
H. Burris III and C. Rocha-Lima
New Therapeutic Directions for Advanced Pancreatic Cancer: Targeting the Epidermal Growth Factor and Vascular Endothelial Growth Factor Pathways
Oncologist, March 1, 2008; 13(3): 289 - 298.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
S. Boeck, T. Hoehler, G. Seipelt, R. Mahlberg, A. Wein, A. Hochhaus, H.-P. Boeck, B. Schmid, E. Kettner, M. Stauch, et al.
Capecitabine plus oxaliplatin (CapOx) versus capecitabine plus gemcitabine (CapGem) versus gemcitabine plus oxaliplatin (mGemOx): final results of a multicenter randomized phase II trial in advanced pancreatic cancer
Ann. Onc., February 1, 2008; 19(2): 340 - 347.
[Abstract] [Full Text] [PDF]

Home page
 J Oncol PractHome page
M. A. Tempero
How I Treat Pancreatic Ductal Adenocarcinoma
J. Oncol. Pract, January 1, 2008; 4(1): 46 - 47.
[Full Text] [PDF]

Home page
 JCOHome page
S. P. Desai, E. Ben-Josef, D. P. Normolle, I. R. Francis, J. K. Greenson, D. M. Simeone, A. E. Chang, L. M. Colletti, T. S. Lawrence, and M. M. Zalupski
Phase I Study of Oxaliplatin, Full-Dose Gemcitabine, and Concurrent Radiation Therapy in Pancreatic Cancer
J. Clin. Oncol., October 10, 2007; 25(29): 4587 - 4592.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
V. Heinemann, R. Labianca, A. Hinke, and C. Louvet
Increased survival using platinum analog combined with gemcitabine as compared to single-agent gemcitabine in advanced pancreatic cancer: pooled analysis of two randomized trials, the GERCOR/GISCAD intergroup study and a German multicenter study
Ann. Onc., October 1, 2007; 18(10): 1652 - 1659.
[Abstract] [Full Text] [PDF]

Home page
 Jpn J Clin OncolHome page
H. Ueno, T. Okusaka, M. Ikeda, C. Morizane, T. Ogura, A. Hagihara, and T. Tanaka
Phase II Study of Combination Chemotherapy with Gemcitabine and Cisplatin for Patients with Metastatic Pancreatic Cancer
Jpn. J. Clin. Oncol., August 2, 2007; (2007) hym060v1.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
R. Herrmann, G. Bodoky, T. Ruhstaller, B. Glimelius, E. Bajetta, J. Schuller, P. Saletti, J. Bauer, A. Figer, B. Pestalozzi, et al.
Gemcitabine Plus Capecitabine Compared With Gemcitabine Alone in Advanced Pancreatic Cancer: A Randomized, Multicenter, Phase III Trial of the Swiss Group for Clinical Cancer Research and the Central European Cooperative Oncology Group
J. Clin. Oncol., June 1, 2007; 25(16): 2212 - 2217.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
E. Van Cutsem, C. Verslype, and P. A. Grusenmeyer
Lessons Learned in the Management of Advanced Pancreatic Cancer
J. Clin. Oncol., May 20, 2007; 25(15): 1949 - 1952.
[Full Text] [PDF]

Home page
 JCOHome page
R. R. McWilliams and S. R. Alberts
Gemcitabine Plus Cisplatin in Advanced Pancreatic Cancer
J. Clin. Oncol., March 20, 2007; 25(9): 1142 - 1142.
[Full Text] [PDF]

Home page
 JCOHome page
V. Heinemann and S. Boeck
In Reply
J. Clin. Oncol., March 20, 2007; 25(9): 1142 - 1143.
[Full Text] [PDF]


About
JCO		 Editorial
Roster		 Advertising
Information		 Librarians &
Institutions		 Rights &
Permissions		 PDA Services

Copyright © 2006 by the American Society of Clinical Oncology, Online ISSN: 1527-7755. Print ISSN: 0732-183X
Terms and Conditions of Use
  HighWire Press HighWire Press™ assists in the publication of JCO Online